Remicade (infliximab) — Competitive Intelligence Brief

Remicade (infliximab) (Remicade (infliximab)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (tumor necrosis factor-alpha) Immunology Biologic

Target snapshot

Remicade (infliximab) (Remicade (infliximab)) — Merck Sharp & Dohme LLC. Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Remicade (infliximab) TARGET	Remicade (infliximab)	Merck Sharp & Dohme LLC	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Humira® (Adalimumab)	Humira® (Adalimumab)	Mylan Inc.	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Smartject Device delivery of Golimumab	Smartject Device delivery of Golimumab	Merck Sharp & Dohme LLC	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Infliximab (Remicade)	Infliximab (Remicade)	University of California, San Diego	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Adalimumab (ADA)	Adalimumab (ADA)	JHSPH Center for Clinical Trials	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Golimumab (GLM)	Golimumab (GLM)	University College Dublin	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Start adalimumab in monotherapy	Start adalimumab in monotherapy	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 drugs in this class
3. Hanyang University Seoul Hospital · 2 drugs in this class
4. Biocad · 1 drug in this class
5. Children's Memorial Health Institute, Poland · 1 drug in this class
6. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class
7. Centocor, Inc. · 1 drug in this class
8. Hikma Pharmaceuticals LLC · 1 drug in this class
9. Hospital de Manises · 1 drug in this class
10. Celltrion · 1 drug in this class